Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for Hailey-Hailey disease (single-center randomized open-label trial)
ChiCTR2500102331Phase 4Recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of botulinum toxin type A in Hailey-Hailey disease (HHD) (2 arms), sponsored by Ruijin Hospital. Primary endpoint: IGA75 remission rate at week 24. Started May 2025; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
Hailey-Hailey disease (HHD)
Beyond the preview
Go deeper on ChiCTR2500102331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500102331.